Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Gitlab Inc (GTLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Gitlab Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.83 (market cap $4.49B), while Gitlab Inc trades at $31.88 (market cap $5.50B). The key difference: Gitlab Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | GTLB | |
|---|---|---|
Market Cap | $4.49B | $5.50B |
Sector | Health | Technology |
52-Week High | $28.06 | $51.04 |
52-Week Low | $20.06 | $19.42 |
Enterprise Value | $3.69B | $4.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
GitLab (GTLB) trades at $32.59, up 1.62% today, with a bullish technical signal and recent earnings beats. The stock shows strong revenue growth, reaching $759 million in 2025, but remains unprofitable with a negative net margin. Analyst sentiment is mixed, with a consensus price target of $31.86, while recent news highlights its leadership in DevSecOps and AI-driven software development.
Outlook: GitLab's growth trajectory and strategic position in AI and DevSecOps present upside potential, but profitability concerns and high valuation ratios pose risks. Investors should weigh strong revenue expansion against ongoing losses and competitive pressures in the technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
